Clinical Trial: Mechanism of Synergistic Enhancement of Ivonescimab in Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07359040) titled 'Mechanism of Synergistic Enhancement of Ivonescimab in Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer' on Jan. 13.

Brief Summary: This study primarily aims to compare the efficacy of anti-angiogenic therapy combined with a PD-1 inhibitor (Ivonescimab) versus PD-1 inhibitor monotherapy as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). Additionally, it will investigate the potential synergistic mechanisms of Ivonescimab to provide an evidence-based rationale for its clinical application.

Study Start Date: Jan. 31

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer Neoadjuvant T...